Previous close | 0.3044 |
Open | 0.3000 |
Bid | 0.2900 x 800 |
Ask | 0.3150 x 800 |
Day's range | 0.2888 - 0.3100 |
52-week range | 0.0920 - 0.6500 |
Volume | |
Avg. volume | 872,595 |
Market cap | 11.006M |
Beta (5Y monthly) | 1.38 |
PE ratio (TTM) | 0.81 |
EPS (TTM) | 0.3600 |
Earnings date | 29 Mar 2023 - 03 Apr 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 13 Jan 2023 |
1y target est | 16.00 |
Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst”) and GNI Group Ltd. (21
Catalyst Biosciences ( NASDAQ:CBIO ) Third Quarter 2022 Results Key Financial Results Net loss: US$4.88m (loss narrowed...
Over the last year, a good number of insiders have significantly increased their holdings in Catalyst Biosciences, Inc...